US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Medicus Pharma Ltd.

0.1614

-0.0090-5.28%

Post-market: 0.1595-0.0019-1.18%19:59 EDT

Volume:18.16M

Turnover:3.14M

Market Cap:10.20M

PE:-0.10

High:0.1724

Open:0.1718

Low:0.1570

Close:0.1704

52wk High:3.05

52wk Low:0.1512

Shares:63.18M

Float Shares:56.90M

Volume Ratio:0.64

T/O Rate:31.92%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6597

EPS(LYR):-2.7356

ROE:-7446.11%

ROA:-110.67%

PB:-5.78

PE(LYR):-0.06

Loading ...

Overview Company News Filings

Medicus Pharma FY26 Q2 Net Loss Widens 89.1% to $11.68 Million

Medicus Pharma Ltd Expected to Post a Loss of 13 Cents a Share - Earnings Preview

Medicus UK Unit Antev Names Faisal Mehmud CEO Effective Aug. 30

Medicus Pharma Appoints DR. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

THOMSON REUTERS

Press Release: Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

Medicus Pharma - UAE Department of Health Grants Ind Authorization for Precision-E2 Phase 2a Study of Teverelix

THOMSON REUTERS

Medicus Pharma Wins UAE DOH IND Clearance for Teverelix Endometriosis Phase 2a Trial

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

Medicus Pharma gets FDA green light for SkinJect Phase 2b Gorlin study

Medicus Pharma Wins FDA Clearance to Start SkinJect Registrational Gorlin Syndrome Trial

Medicus Pharma Receives FDA “Study May Proceed” Letter for Nda-Enabling Registrational Skinject® Study in Patients with Gorlin Syndrome

THOMSON REUTERS

Medicus Pharma Wins FDA Backing for Optimized Phase 2 Teverelix Study in Acute Urinary Retention

Medicus Pharma - Central Irb Approves Ant-2111-02 Protocol with Modifications Through June 18, 2027

THOMSON REUTERS

Medicus Pharma Receives Positive FDA Feedback and Central Irb Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention

THOMSON REUTERS

Medicus Pharma - Phase 2 Study Ant-2111-02 to Evaluate Teverelix DP in Acute Urinary Retention

THOMSON REUTERS

Medicus Pharma to present at Bio International Conference, outlining SkinJect registrational plan

Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026

Medicus Pharma submits FDA rare pediatric disease designation request for SkinJect in Gorlin syndrome

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for Skinject® in Gorlin Syndrome

THOMSON REUTERS

Medicus Pharma Submits Drug Application for Genomics-Driven Teverelix Phase 2a Study

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/MDCX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":0.1614,"timestamp":1789070400000,"preClose":0.1704,"halted":0,"volume":18164197,"hourTrading":{"tag":"盘后","latestPrice":0.159501,"preClose":0.1614,"latestTime":"19:59 EDT","volume":887286,"amount":142298.89452,"timestamp":1789084777801,"change":-0.001899,"changeRate":-0.011766,"amplitude":0.043371},"delay":0,"changeRate":-0.05281690140845075,"floatShares":56901000,"shares":63180610,"eps":-1.659689,"marketStatus":"Closed","change":-0.009,"latestTime":"09-10 16:00:00 EDT","open":0.1718,"high":0.1724,"low":0.157,"amount":3142930.2997254203,"amplitude":0.090376,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.659689,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789113600000},"marketStatusCode":5,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":0.1704,"preHourTrading":{"tag":"盘前","latestPrice":0.17,"preClose":0.1704,"latestTime":"09:29 EDT","volume":6612869,"amount":1170465.11629152,"timestamp":1789046999371,"change":-0.0004,"changeRate":-0.002347,"amplitude":0.158451},"postHourTrading":{"tag":"盘后","latestPrice":0.159501,"preClose":0.1614,"latestTime":"19:59 EDT","volume":887286,"amount":142298.89452,"timestamp":1789084777801,"change":-0.001899,"changeRate":-0.011766,"amplitude":0.043371},"volumeRatio":0.643152},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":56901000,"roa":"-110.67%","roe":"-7446.11%","lyrEps":-2.735593,"volumeRatio":0.643152,"shares":63180610,"dividePrice":0,"high":0.1724,"amplitude":0.090376,"preClose":0.1704,"low":0.157,"week52Low":0.1512,"pbRate":"-5.78","week52High":3.05,"institutionHeld":0,"latestPrice":0.1614,"eps":-1.659689,"divideRate":0,"volume":18164197,"delay":0,"ttmEps":-1.659689,"open":0.1718,"prevYearClose":1.53,"prevWeekClose":0.172,"prevMonthClose":0.2618,"prevQuarterClose":0.4463,"fiveDayClose":0.2599,"twentyDayClose":0.3311,"sixtyDayClose":0.32},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"MDCX","fiscalQuarterEnding":"2026/06","expectedEps":-0.14,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2026-05-14","symbol":"MDCX","fiscalQuarterEnding":"2026/03","expectedEps":-0.18,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.31},{"market":"US","date":"2026-03-25","symbol":"MDCX","fiscalQuarterEnding":"2025/12","expectedEps":-0.32,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774411200000,"reportTimeType":"post","actualEps":-0.82},{"date":"2025-11-14","symbol":"MDCX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763154000000,"name":null,"time":"Post-Mkt","dateTimestamp":1763096400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1785297600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MDCX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MDCX","date":"2026-09-09","current":-0.097247,"percent":1,"low":-3.23298,"twenty":-2.167912,"median":-0.736109,"eighty":-0.336268,"high":-0.189555,"avg":-1.083424,"sd":0.948792,"marketCap":10740703},"quantilePoints":[{"date":"2025-08-29","current":-2.084531,"twenty":-2.272139,"median":-2.126221,"eighty":-2.109545,"marketCap":35632532},{"date":"2025-09-05","current":-1.907346,"twenty":-2.205434,"median":-2.115799,"eighty":-2.053263,"marketCap":32603766},{"date":"2025-09-12","current":-2.345097,"twenty":-2.211687,"median":-2.12101,"eighty":-2.053263,"marketCap":40086598},{"date":"2025-09-19","current":-2.532705,"twenty":-2.511859,"median":-2.178335,"eighty":-2.080362,"marketCap":43293526},{"date":"2025-09-26","current":-2.817408,"twenty":-2.759151,"median":-2.287772,"eighty":-2.103292,"marketCap":48160186},{"date":"2025-10-03","current":-3.005474,"twenty":-2.869667,"median":-2.511859,"eighty":-2.115799,"marketCap":51374941},{"date":"2025-10-10","current":-3.005474,"twenty":-2.994879,"median":-2.558762,"eighty":-2.122052,"marketCap":51374941},{"date":"2025-10-17","current":-2.885734,"twenty":-2.976858,"median":-2.720313,"eighty":-2.151236,"marketCap":49328130},{"date":"2025-10-24","current":-2.909682,"twenty":-2.974342,"median":-2.774974,"eighty":-2.174166,"marketCap":49737492},{"date":"2025-10-31","current":-2.957578,"twenty":-2.974342,"median":-2.817408,"eighty":-2.178335,"marketCap":50556216},{"date":"2025-11-07","current":-2.897708,"twenty":-2.962368,"median":-2.809662,"eighty":-2.228364,"marketCap":49532811},{"date":"2025-11-14","current":-2.706124,"twenty":-2.950394,"median":-2.817408,"eighty":-2.292984,"marketCap":46257915},{"date":"2025-11-21","current":-1.28141,"twenty":-2.950394,"median":-2.789942,"eighty":-2.178335,"marketCap":44939453},{"date":"2025-11-28","current":-1.355609,"twenty":-2.936025,"median":-2.763,"eighty":-2.119968,"marketCap":48464116},{"date":"2025-12-05","current":-1.183077,"twenty":-2.916866,"median":-2.742046,"eighty":-2.04284,"marketCap":42295956},{"date":"2025-12-12","current":-1.201563,"twenty":-2.904892,"median":-2.700137,"eighty":-1.376181,"marketCap":42956830},{"date":"2025-12-19","current":-1.022869,"twenty":-2.897708,"median":-2.63428,"eighty":-1.31987,"marketCap":36568379},{"date":"2025-12-26","current":-0.955088,"twenty":-2.897553,"median":-2.584818,"eighty":-1.266827,"marketCap":34145173},{"date":"2026-01-02","current":-1.074791,"twenty":-2.896932,"median":-2.511859,"eighty":-1.220048,"marketCap":38424640},{"date":"2026-01-09","current":-1.095865,"twenty":-2.885734,"median":-2.329463,"eighty":-1.179996,"marketCap":39178064},{"date":"2026-01-16","current":-0.976444,"twenty":-2.885734,"median":-2.178335,"eighty":-1.123965,"marketCap":34908660},{"date":"2026-01-23","current":-0.94132,"twenty":-2.866576,"median":-2.167912,"eighty":-1.101485,"marketCap":33652952},{"date":"2026-01-30","current":-0.878097,"twenty":-2.861786,"median":-2.115799,"eighty":-1.061072,"marketCap":31392680},{"date":"2026-02-06","current":-0.765701,"twenty":-2.861786,"median":-2.074108,"eighty":-1.022014,"marketCap":27374416},{"date":"2026-02-13","current":-0.709738,"twenty":-2.853549,"median":-1.933403,"eighty":-0.974021,"marketCap":25373688},{"date":"2026-02-20","current":-0.786136,"twenty":-2.850483,"median":-1.381324,"eighty":-0.961937,"marketCap":28104981},{"date":"2026-02-27","current":-0.97195,"twenty":-2.849812,"median":-1.344224,"eighty":-0.949581,"marketCap":34747976},{"date":"2026-03-06","current":-0.484474,"twenty":-2.849812,"median":-1.300152,"eighty":-0.949581,"marketCap":17320333},{"date":"2026-03-13","current":-0.412761,"twenty":-2.835443,"median":-1.263181,"eighty":-0.891018,"marketCap":14756541},{"date":"2026-03-20","current":-0.412761,"twenty":-2.825864,"median":-1.220048,"eighty":-0.847322,"marketCap":14756541},{"date":"2026-03-27","current":-0.387698,"twenty":-2.82079,"median":-1.201563,"eighty":-0.836077,"marketCap":18330934},{"date":"2026-04-02","current":-0.349652,"twenty":-2.811211,"median":-1.179996,"eighty":-0.820403,"marketCap":16532085},{"date":"2026-04-10","current":-0.367967,"twenty":-2.792337,"median":-1.125793,"eighty":-0.786136,"marketCap":17398052},{"date":"2026-04-17","current":-0.250001,"twenty":-2.775573,"median":-1.109135,"eighty":-0.744685,"marketCap":11820441},{"date":"2026-04-24","current":-0.276475,"twenty":-2.764797,"median":-1.099378,"eighty":-0.508201,"marketCap":13072156},{"date":"2026-05-01","current":-0.235266,"twenty":-2.75402,"median":-1.088841,"eighty":-0.417566,"marketCap":11123732},{"date":"2026-05-08","current":-0.277717,"twenty":-2.74923,"median":-1.069002,"eighty":-0.412761,"marketCap":13130880},{"date":"2026-05-15","current":-0.393186,"twenty":-2.733353,"median":-1.041354,"eighty":-0.401798,"marketCap":18590424},{"date":"2026-05-22","current":-0.308017,"twenty":-2.714637,"median":-1.024243,"eighty":-0.38811,"marketCap":15777036},{"date":"2026-05-29","current":-0.354651,"twenty":-2.703729,"median":-1.018593,"eighty":-0.376126,"marketCap":18165658},{"date":"2026-06-05","current":-0.402361,"twenty":-2.691755,"median":-0.976444,"eighty":-0.374724,"marketCap":20609444},{"date":"2026-06-12","current":-0.35842,"twenty":-2.672597,"median":-0.968141,"eighty":-0.372398,"marketCap":18358733},{"date":"2026-06-18","current":-0.378775,"twenty":-2.63428,"median":-0.962395,"eighty":-0.367967,"marketCap":19401342},{"date":"2026-06-26","current":-0.492235,"twenty":-2.63428,"median":-0.955088,"eighty":-0.371628,"marketCap":25212882},{"date":"2026-07-02","current":-0.442458,"twenty":-2.59471,"median":-0.94132,"eighty":-0.37203,"marketCap":22663265},{"date":"2026-07-10","current":-0.467347,"twenty":-2.543128,"median":-0.915037,"eighty":-0.3732,"marketCap":23938074},{"date":"2026-07-17","current":-0.449095,"twenty":-2.516028,"median":-0.871896,"eighty":-0.374395,"marketCap":23003214},{"date":"2026-07-24","current":-0.424981,"twenty":-2.511859,"median":-0.846653,"eighty":-0.374627,"marketCap":21768066},{"date":"2026-07-31","current":-0.290474,"twenty":-2.411802,"median":-0.843141,"eighty":-0.371929,"marketCap":14878433},{"date":"2026-08-07","current":-0.34025,"twenty":-2.326336,"median":-0.835949,"eighty":-0.363051,"marketCap":17428051},{"date":"2026-08-14","current":-0.353971,"twenty":-2.282561,"median":-0.821824,"eighty":-0.360424,"marketCap":20056990},{"date":"2026-08-21","current":-0.30351,"twenty":-2.211687,"median":-0.793282,"eighty":-0.354379,"marketCap":17197762},{"date":"2026-08-28","current":-0.298604,"twenty":-2.178335,"median":-0.778989,"eighty":-0.346389,"marketCap":16919767},{"date":"2026-09-04","current":-0.190112,"twenty":-2.172081,"median":-0.757549,"eighty":-0.339549,"marketCap":10772294},{"date":"2026-09-09","current":-0.189555,"twenty":-2.167912,"median":-0.736109,"eighty":-0.336268,"marketCap":10740703}],"updateTime":1789092113938},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659424183","title":"Medicus Pharma FY26 Q2 Net Loss Widens 89.1% to $11.68 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659424183","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659424183?lang=en_us&edition=fundamental","pubTime":"2026-08-13 05:21","pubTimestamp":1786569697,"startTime":"0","endTime":"0","summary":"Medicus Pharma FY26 Q2 net loss widens 89.1% to $11.68 millionMedicus Pharma posted a Q2 net loss of USD 11.68 million, widening from USD 6.18 million a year earlier.Operating loss widened to USD 11.48 million as total operating expenses rose 90.8% to USD 11.48 million.General and administrative costs climbed 43.6% to USD 6.57 million; R&D spending more than doubled to USD 4.91 million.Cash and cash equivalents were USD 15.17 million at June 30, with USD 10.02 million of restricted cash and working capital of USD 6.14 million.FDA issued a “Study May Proceed” letter for SkinJect’s SKNJCT-005 Phase 2b registrational trial; UAE DOH authorized Teverelix PRECISION-E2 Phase 2a.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLcdLr7D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657290136","title":"Medicus Pharma Ltd Expected to Post a Loss of 13 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657290136","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657290136?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:35","pubTimestamp":1786138521,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd <MDCX.OQ> expected to post a loss of13cents a share - Earnings PreviewMedicus Pharma LtdMDCX.OQMDCX.Ois expected to  show no change in quarterly revenue when it reports  results on ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4442LF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656375917","title":"Medicus UK Unit Antev Names Faisal Mehmud CEO Effective Aug. 30","url":"https://stock-news.laohu8.com/highlight/detail?id=2656375917","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656375917?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:30","pubTimestamp":1785756631,"startTime":"0","endTime":"0","summary":"Medicus UK unit Antev names Faisal Mehmud CEO effective Aug. 30Medicus’ UK subsidiary Antev named Faisal Mehmud CEO, effective Aug. 30, 2026.Mehmud keeps roles as Medicus chief medical officer, Antev ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL9Bf2Kx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4585","BK4588","IE00BN0W2T93.GBP","SG9999014021.USD","LU2210149790.SGD","SG9999014005.SGD","NDAQ","BK4139","LU2095319765.USD","LU0314104364.USD","IE00B64PRP62.GBP","MDCX","BCDF","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014039.USD","BK4112","LU2210150020.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656375980","title":"Medicus Pharma Appoints DR. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2656375980","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656375980?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:30","pubTimestamp":1785756600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUA8KSWWB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656375165","title":"Press Release: Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2656375165","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656375165?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:30","pubTimestamp":1785756600,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (\"Medicus\" or the \"Company\"), a biotech/life sciences company focused on advancing the clinical development programs ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4104","BK4528","BK4211","BK4022","UBCP","BK4233","MDCX","UK","BK4567","BK4205","BCC","BK4232","MRCP","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655363165","title":"Medicus Pharma - UAE Department of Health Grants Ind Authorization for Precision-E2 Phase 2a Study of Teverelix","url":"https://stock-news.laohu8.com/highlight/detail?id=2655363165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655363165?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:30","pubTimestamp":1785497426,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X0OR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655363467","title":"Medicus Pharma Wins UAE DOH IND Clearance for Teverelix Endometriosis Phase 2a Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2655363467","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655363467?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:30","pubTimestamp":1785497424,"startTime":"0","endTime":"0","summary":"Medicus Pharma wins UAE DOH IND clearance for Teverelix endometriosis Phase 2a trialMedicus Pharma won UAE Department of Health IND clearance to start the PRECISION-E2 Phase 2a Teverelix study in mode","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL1jRj2g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4112","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","LU2095319765.USD","IE00BN0W2V16.EUR","BK4139","SG9999014039.USD","NDAQ","BCDF","MDCX","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU0314104364.USD","BK4588","IE00BN0W2W23.USD","LU2210149790.SGD","SG9999014005.SGD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655632143","title":"Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2655632143","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655632143?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:30","pubTimestamp":1785497400,"startTime":"0","endTime":"0","summary":"Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's healthPHILADELPHIA, July  31, 2026  (GLOBE NEWSWIRE) -- Medicus Phar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/31/3336735/0/en/Medicus-Pharma-Receives-UAE-Department-of-Health-DOH-Authorization-to-proceed-with-Novel-Prospective-Genomics-Guided-Precision-Medicine-Study-Evaluating-Teverelix-in-Women-with-End.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2746668974.SGD","LU2746668461.USD","LU2237443978.SGD","IE00BFXG1179.USD","BK4006","IE00B1BXHZ80.USD","LU0170899867.USD","BK4104","LU0149725797.USD","IE00BHPRN162.USD","BK4139","LU0971096721.USD","LU2237443895.HKD","LU2237443549.SGD","IE00BZ1G4Q59.USD","LU2237443382.USD","MDCX","CMC","LU2237443465.HKD","UAE","IE00BKVL7J92.USD","LU1363072403.SGD","LU0882574139.USD","LU2237443622.USD","BK4567","LU0267386448.USD","BCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654322043","title":"Medicus Pharma gets FDA green light for SkinJect Phase 2b Gorlin study","url":"https://stock-news.laohu8.com/highlight/detail?id=2654322043","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654322043?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:10","pubTimestamp":1785157848,"startTime":"0","endTime":"0","summary":"Medicus Pharma (MDCX) announced the FDA has completed its safety review of the company’s Investigational New Drug application for SKNJCT-005 and is...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicus-pharma-gets-fda-green-light-for-skinject-phase-2b-gorlin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicus-pharma-gets-fda-green-light-for-skinject-phase-2b-gorlin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","MDCX","BK4585","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654301704","title":"Medicus Pharma Wins FDA Clearance to Start SkinJect Registrational Gorlin Syndrome Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654301704","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654301704?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:17","pubTimestamp":1785154645,"startTime":"0","endTime":"0","summary":"Medicus Pharma wins FDA clearance to start SkinJect registrational Gorlin syndrome trialMedicus received an FDA “study may proceed” letter, clearing its SKNJCT-005 Phase 2b registrational trial of Ski","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL6zgbh8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BKPKM429.USD","MDCX","SG9999014005.SGD","BK4139","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BN0W2W23.USD","BK4585","LU0314104364.USD","SG9999014039.USD","BK4112","LU2210150020.SGD","LU2095319765.USD","BK4588","BCDF","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654501701","title":"Medicus Pharma Receives FDA “Study May Proceed” Letter for Nda-Enabling Registrational Skinject® Study in Patients with Gorlin Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2654501701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654501701?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:17","pubTimestamp":1785154620,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUARLLQZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651449586","title":"Medicus Pharma Wins FDA Backing for Optimized Phase 2 Teverelix Study in Acute Urinary Retention","url":"https://stock-news.laohu8.com/highlight/detail?id=2651449586","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651449586?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:30","pubTimestamp":1784201440,"startTime":"0","endTime":"0","summary":"Medicus Pharma wins FDA backing for optimized Phase 2 Teverelix study in acute urinary retentionMedicus received FDA written feedback backing an optimized Phase 2 Teverelix study in acute urinary rete","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDL3PC0C2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","SG9999014039.USD","SG9999014005.SGD","BCDF","LU0314104364.USD","NDAQ","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BGHQF748.EUR","MDCX","SG9999014013.SGD","IE00BKPKM429.USD","BK4585","IE00B64PRP62.GBP","IE00BN0W2W23.USD","LU2210150020.SGD","BK4112","SG9999014021.USD","IE00BN0W2T93.GBP","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651644934","title":"Medicus Pharma - Central Irb Approves Ant-2111-02 Protocol with Modifications Through June 18, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2651644934","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651644934?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:30","pubTimestamp":1784201401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nTUABKZ8WK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651544932","title":"Medicus Pharma Receives Positive FDA Feedback and Central Irb Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention","url":"https://stock-news.laohu8.com/highlight/detail?id=2651544932","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651544932?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:30","pubTimestamp":1784201401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nTUABKZ8WK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651449367","title":"Medicus Pharma - Phase 2 Study Ant-2111-02 to Evaluate Teverelix DP in Acute Urinary Retention","url":"https://stock-news.laohu8.com/highlight/detail?id=2651449367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651449367?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:30","pubTimestamp":1784201401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nTUABKZ8WK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645021185","title":"Medicus Pharma to present at Bio International Conference, outlining SkinJect registrational plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2645021185","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645021185?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:30","pubTimestamp":1782127831,"startTime":"0","endTime":"0","summary":"Medicus will attend the Bio International Conference in San Diego on June 22-25, 2026.A company presentation is scheduled for June 24, 2026 at 3:00 p.m. Pacific time at the San Diego Convention Center.Update expected on SkinJect registrational plans following Phase 2 results showing 55% histological clearance, 64% clinical clearance in the 200 ug cohort.Teverelix precision-medicine endometriosis study update expected, alongside broader development plans in prostate cancer and urology.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL14SFcj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014039.USD","LU2210150020.SGD","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014013.SGD","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","BK4585","BK4588","LU2095319765.USD","SG9999014021.USD","MDCX","SG9999014005.SGD","IE00BN0W2W23.USD","BK4112","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","NDAQ","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645021486","title":"Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645021486","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645021486?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:30","pubTimestamp":1782127800,"startTime":"0","endTime":"0","summary":"Company’s presentation will provide updates on SkinJect Phase 2b Pivotal Study in patients with Gorlin Syndrome and Teverelix Groundbreaking PRECISION-E2 Phase 2a Endometriosis Study leveraging the UA","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/22/3315195/0/en/Medicus-Pharma-to-Showcase-SkinJect-Registrational-Strategy-and-Teverelix-Precision-Medicine-Program-at-Bio-International-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","MDCX","BCC","BK4567","BK4183","UAE","BK4104","IE0009354923.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643322208","title":"Medicus Pharma submits FDA rare pediatric disease designation request for SkinJect in Gorlin syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2643322208","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643322208?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:30","pubTimestamp":1781523035,"startTime":"0","endTime":"0","summary":"Medicus Pharma submitted an FDA Rare Pediatric Disease Designation request for SkinJect to treat basal cell carcinoma in Gorlin syndrome patients.The filing follows an orphan drug designation application; the registrational study design remains under FDA review.Phase 2 data showed 64% clinical clearance, 55% complete response in the 200 ug arm.If granted and later approved, the designation could support eligibility for a rare pediatric disease priority review voucher.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL7TvKMn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","MDCX","LU2210149790.SGD","LU2095319765.USD","BK4139","IE00B3QW5Z07.USD","LU0314104364.USD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4585","IE00BKPKM429.USD","SG9999014013.SGD","BK4588","IE00BN0W2T93.GBP","BK4112","SG9999014021.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643316208","title":"Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for Skinject® in Gorlin Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2643316208","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643316208?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:30","pubTimestamp":1781523000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA12V8J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642849952","title":"Medicus Pharma Submits Drug Application for Genomics-Driven Teverelix Phase 2a Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2642849952","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642849952?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:30","pubTimestamp":1781181027,"startTime":"0","endTime":"0","summary":"Medicus Pharma  said it submitted an Investigational New Drug application for the PRECISION-E2 Phase 2a study of Teverelix in women with symptomatic endometriosis, using the Emirati Genome Program to evaluate genomic predictors of treatment response, the company said Thursday.The study, submitted to the Department of Health Abu Dhabi as an Investigational New Drug application, is a randomized, placebo-controlled trial in about 84 patients in the UAE assessing safety, efficacy, pharmacodynamics and genomic response, the company said.Medicus said the trial will combine clinical, hormonal, pharmacokinetic and genomic data to assess treatment response variability while targeting controlled estradiol suppression and limiting side effects.The study could support further Phase 2b development of Teverelix and expansion into other estrogen-driven indications, while generating an integrated clinical and genomic precision-medicine dataset, it added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":105,"code":"91000000","status":"200"}]}}